Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.78 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
From Pfizer Inc.
Via Business Wire
Dynamic Global Events Presents: The 6th Clinical Trial Agreements Summit
Via Investor Brand Network
Topics Intellectual Property
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
From Pfizer Inc.
Via Business Wire
Kwizda Pharma Adopts CARA Life Sciences Platform for Rapid QMS Implementation with Minimal IT Resources
LONDON - April 30, 2025 - PRLog -- Kwizda Pharma, a division of Kwizda Holding GmbH and a leader in the Austrian healthcare market, has selected the CARA Life Sciences Platform from Generis, leading... 
Via PRLog
Topics Artificial Intelligence
Pfizer Declares Third-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)? 
Via News Direct
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
From Berger Montague
Via GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
Via Investor Brand Network
Topics Lawsuit
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
From FN Media Group LLC
Via GlobeNewswire
Michael McTague: Watch out for these killer superbugs that resist today’s antibiotics
These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them? It appears that these devils 
Via Equities.com
Topics Death
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
From Levin Papantonio
Via Business Wire
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
From Pfizer Inc.
Via Business Wire
Ireland: America’s Gateway to Europe – The $2 Trillion Investment Story
Via AB Newswire
Cytonics Selects CARA Life Sciences Platform for Rapid eTMF System Implementation
Via PRLog
Topics Artificial Intelligence
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
From Pfizer Inc.
Via Business Wire
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
Pfizer Declares Second-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
From Pfizer Inc.
Via Business Wire
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
From Pfizer Inc.
Via Business Wire
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga 
Via TheNewswire.com
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.